ACT 077825

Drug Profile

ACT 077825

Alternative Names: Act-AAA

Latest Information Update: 27 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Actelion Pharmaceuticals; Merck & Co
  • Developer Actelion Pharmaceuticals
  • Class Cardiovascular therapies
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
  • 19 Jul 2012 Merck and Actelion terminate their collaboration in renin inhibitors
  • 18 Mar 2005 Actelion achieved its second milestone in regard to the renin alliance with Merck & Co and has moved its first compound into full preclinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top